Desmetramadol
Pain
Clinical DevelopmentActive
Key Facts
About Syntrix Pharmaceuticals
Syntrix Pharmaceuticals is a private, clinical-stage biotech company leveraging a technology-agnostic, needs-driven research approach to develop novel therapeutics. Its pipeline features advanced clinical candidates in immuno-oncology (SX-682) and pain (desmetramadol), supported by a lean management team and a prestigious network of scientific advisors from top cancer centers. The company's strategy combines internal medicinal chemistry discovery with external collaboration and potential strategic acquisitions to build a robust portfolio targeting cancer and inflammatory diseases.
View full company profileTherapeutic Areas
Other Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Oxycodone Patch | Avecho Biotechnology | Preclinical |
| Oxymorphone Patch | Avecho Biotechnology | Preclinical |
| Diclofenac Potassium Powder for Oral Solution | Patrin Pharma | Approved |
| CG001419 | Cullgen | Phase 1 |
| Proprietary Pain Program(s) | Oblique Therapeutics | Pre-clinical |
| Pain Management APIs | Noramco | Commercial |
| Dipendium (Diclofenac Potassium) | NovaMedica | Approved |
| Na ion channel TicTACs | Solu Therapeutics | Preclinical |
| Infusional Pain Management (e.g., Paracetamol) | Galenica Senese | Commercial |
| NCEs for Pain Management | Ipca Laboratories | Preclinical/Discovery |
| XEN1701 | Xenon Pharmaceuticals | Phase 1 |